Related Experiment Video
Updated: Mar 8, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial
Ming-Shien Wen1,2, Kuan-Cheng Chang3,4, Tsong-Hai Lee1,5
1College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Aim:
This study aimed to determine clinical utility of genotype-guided dosing for warfarin in Han-Chinese.
Methods:
A total of 320 patients were randomly assigned International Warfarin Pharmacogenetic Consortium algorithm, Taiwan algorithm and optimal clinical care arms. The primary outcome of the study was the percentage of time in the therapeutic range during the first 90 days of treatment.
Results:
The percentage of time in the therapeutic range of the clinical care group in the first 2 weeks was significantly higher than the algorithm groups. This difference was no longer observed after 4 weeks. No difference in excessive anticoagulation (international normalized ratio ≥4.0) and adverse events was observed.
Conclusion:
Genotype-guided dosing did not provide significant benefit. Loading dose with frequent international normalized ratio monitoring could provide sufficient control of anticoagulation.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Principles of Pharmacogenetics: Types of Genetic Variants
Drug toxicity: Idiosyncratic Reactions
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacodynamics in Geriatric Patients: Effects of Age